This Phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in China. The purpose of the study is to learn about the safety and immune response of 20vPnC and 13vPnC in Chinese adults 50 years of age and older who did not receive any of pneumococcal vaccine in the past
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of participants reporting prompted local reactions within 7 days following investigational product administration
Timeframe: Within 7 days after vaccination
Percentage of participants reporting prompted systemic events within 7 days following investigational product administration
Timeframe: Within 7 days after vaccination
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
Timeframe: Within 1 month after vaccination
Percentage of participants reporting serious adverse events (SAEs) throughout the study
Timeframe: Within 6 months after vaccination
Percentage of participants reporting abnormal hematology, biochemistry, and urinalysis and microscopy laboratory values
Timeframe: 3 to 5 days after vaccination